The drug Modafinil finally reachs the shores of the United States
as well as links provided to further explore this, the first new medication
and possibly the most effective new treatment for sufferers of sleep disorders
in over 20 years.
Provigil, the long awaited new drug for the treatment of EDS, and Narcolepsy will finally make its long awaited introduction to sufferers of not only these sleep disorders. But also many others as well. Conditions, and perhapes after it's safety is further agreed on, possibly to the general public as a stimulant for ocassional usage.
a article explaining further what Provigil is and who provides it in so
much as it's pharma patent holders etc choose
the link provided "here".
145 Brandywine Parkway
West Chester, PA 19380
Phone: (610) 344-0200
Contact Person: Jason Rubin, VP, Corporate Communications
About Cephalon, Inc.
Founded in 1987, Cephalon, Inc.
is an international
biopharmaceutical company dedicated to the discovery,
development and marketing of innovative products to treat
neurological disorders and cancer. The company is
committed to providing patients and the medical community
with treatment options for diseases where few or no
adequate therapies currently exist.
Headquartered in West Chester, Pennsylvania, Cephalon
currently employs approximately 300 people in the United
States and Europe. The company's European headquarters,
Cephalon U.K. Ltd., is located in Guildford, England and
supports offices in France, Germany and The Benelux
(Belgium, Luxemburg and The Netherlands).
The company's research and development efforts focus
primarily on neurodegenerative disorders, which are
characterized by the death of neurons, the specialized
conducting cells of the nervous system. The company utilizes
its technical expertise in molecular biology, molecular
pharmacology, biochemistry, cell biology and chemistry to
develope products in four core technology areas:
neurotrophic factors, protease inhibitors, signal transduction
modulators and gene transcription regulators. In addition,
Cephalon has been a leader in the development of transgenic
and gene-targeted animal models. Cephalon believes that its
multidisciplinary technology approach facilitates the
development of a portfolio of potential products for the
treatment of neurological disorders such as narcolepsy,
amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease),
multiple sclerosis, peripheral neuropathies, Alzheimer's
disease and stroke. Certain aspects of this technology have
also allowed Cephalon to diversify its therapeutic objectives to
include novel approaches for the treatment of cancer,
especially prostate cancer.
The company has established sales organizations in the
United States, the United Kingdom and France focused on
neurologists and certain other specialists. In the United
States, the company is co-promoting two Bristol-Myers
Squibb proprietary products, Stadol NS® (butorphanol
tartrate), and Serzone® (nefazodone hydrochloride), as well
as Intrathecal Baclofen Therapy (ITB™), a product of
Medtronic Inc. These products are trademarks of Bristol
Myers Squibb and Medtronic, Inc., respectively. In the
United Kingdom, the company is marketing PROVIGIL®
(modafinil) tablets. Under an exclusive sales and marketing
agreement with Laboratoire Aguettant S.A., the company
is marketing Apokinon® (apomorphine hydrochloride) in
A new drug application (NDA) has been filed and is pending
with the U.S. Food and Drug Administration (FDA) for the use
of PROVIGIL in treating the excessive daytime sleepiness
associated with narcolepsy. In May 1998, the company
received authorization to market PROVIGIL in the Republic of
Ireland, and launch is planned following regulatory clearance
of U.S. manufacturing arrangements. The company and
Chiron Corporation have filed an NDA, which is currently under
review with the FDA for the use of MYOTROPHIN®
(mecasermin) Injection in the treatment of ALS. Cephalon and
Chiron are currently providing MYOTROPHIN Injection to a
limited number of patients with ALS in the United States under
a treatment investigation new drug (T-IND) protocol
(MYOTROPHIN Expanded Access Program), which allows
limited distribution of this unapproved drug.
"Cephalon Inc. Talks about Narcolepsy"
Recommendations for Behavioral Therapy "
View the Movie here at these links....
A) View a QuickTime Movie (290 KB)
B) View an AVI using Netscape (1465 KB)
C) View an AVI using MSIE (1465 KB)
For more information about EDS and to receive brochures about EDS and related sleep disorders, call toll-free EDS info line at: 1-800-41-AWAKE
American Sleep Disorders Association
National Sleep Foundation
[the] Sleep Medicine Home Page
Excessive Daytime Sleepiness (EDS) (web site)
- Provigil Approved
In Republic Of Ireland For Narcolepsy
Mar-98 - Provigil Launched In U.K. For Narcolepsy
Journal - Feb 9th 1998
" FDA nears OK on narcolepsy drug "
New Drug Info (web site)
Narcolepsy.org's Provigil Update
Cephalon Inc., Research & Developement (Provigil)
Narcolepsy & Importing (main web site)
Hoover's Company Profiles (Cephalon Inc.)
Touch - Article - " Living
with Narcolepsy "
98/09/16 020 Re: narcolepsy and meds alt.support.narcoleps
98/09/25 019 Re: Exessive Daytime Sleepni alt.support.narcoleps
- A new drug being developed by Cephalon, Inc. for
treatment of narcolepsy "
Fatigue & Modafinil (Provigil)
is it the Ultimate Stimulant? "